| Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial WP Fendler, J Calais, M Eiber, RR Flavell, A Mishoe, FY Feng, ... JAMA oncology 5 (6), 856-863, 2019 | 701 | 2019 |
| Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT M Eiber, K Herrmann, J Calais, B Hadaschik, FL Giesel, M Hartenbach, ... Journal of Nuclear Medicine 59 (3), 469-478, 2018 | 568 | 2018 |
| 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging … J Calais, F Ceci, M Eiber, TA Hope, MS Hofman, C Rischpler, ... The Lancet Oncology 20 (9), 1286-1294, 2019 | 429 | 2019 |
| 68Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL: impact on salvage … J Calais, J Czernin, M Cao, AU Kishan, JV Hegde, N Shaverdian, ... Journal of Nuclear Medicine 59 (2), 230-237, 2018 | 287 | 2018 |
| Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 … TA Hope, M Eiber, WR Armstrong, R Juarez, V Murthy, C Lawhn-Heath, ... JAMA oncology 7 (11), 1635-1642, 2021 | 276 | 2021 |
| Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer WP Fendler, M Weber, A Iravani, MS Hofman, J Calais, J Czernin, H Ilhan, ... Clinical Cancer Research 25 (24), 7448-7454, 2019 | 261 | 2019 |
| Metaanalysis of 68Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology TA Hope, JZ Goodman, IE Allen, J Calais, WP Fendler, PR Carroll Journal of Nuclear Medicine 60 (6), 786-793, 2019 | 257 | 2019 |
| Prostate-specific membrane antigen ligands for imaging and therapy M Eiber, WP Fendler, SP Rowe, J Calais, MS Hofman, T Maurer, ... Journal of Nuclear Medicine 58 (Supplement 2), 67S-76S, 2017 | 241 | 2017 |
| A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER) LF Valle, EJ Lehrer, D Markovic, D Elashoff, R Levin-Epstein, RJ Karnes, ... European urology 80 (3), 280-292, 2021 | 238 | 2021 |
| PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0 WP Fendler, M Eiber, M Beheshti, J Bomanji, J Calais, F Ceci, SY Cho, ... European journal of nuclear medicine and molecular imaging 50 (5), 1466-1486, 2023 | 194 | 2023 |
| Radiation dosimetry and biodistribution of 68Ga-FAPI-46 PET imaging in cancer patients C Meyer, M Dahlbom, T Lindner, S Vauclin, C Mona, R Slavik, J Czernin, ... Journal of Nuclear Medicine 61 (8), 1171-1177, 2020 | 192 | 2020 |
| Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study A Gafita, J Calais, TR Grogan, B Hadaschik, H Wang, M Weber, S Sandhu, ... The Lancet Oncology 22 (8), 1115-1125, 2021 | 189 | 2021 |
| Impact of 68Ga-PSMA-11 PET/CT on the management of prostate cancer patients with biochemical recurrence J Calais, WP Fendler, M Eiber, J Gartmann, FI Chu, NG Nickols, RE Reiter, ... Journal of Nuclear Medicine 59 (3), 434-441, 2018 | 174 | 2018 |
| Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients FL Giesel, C Kratochwil, J Schlittenhardt, K Dendl, M Eiber, F Staudinger, ... European journal of nuclear medicine and molecular imaging 48 (13), 4377-4385, 2021 | 158 | 2021 |
| 68Ga-PSMA-11 PET/CT interobserver agreement for prostate cancer assessments: an international multicenter prospective study WP Fendler, J Calais, M Allen-Auerbach, C Bluemel, N Eberhardt, ... Journal of Nuclear Medicine 58 (10), 1617-1623, 2017 | 152 | 2017 |
| Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2) R Seifert, L Emmett, SP Rowe, K Herrmann, B Hadaschik, J Calais, ... European Urology 83 (5), 405-412, 2023 | 137 | 2023 |
| Impact of 68Ga-PSMA-11 PET/CT on staging and management of prostate cancer patients in various clinical settings: a prospective single-center study I Sonni, M Eiber, WP Fendler, RM Alano, SS Vangala, AU Kishan, ... Journal of Nuclear Medicine 61 (8), 1153-1160, 2020 | 132 | 2020 |
| Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT) C Kratochwil, WP Fendler, M Eiber, MS Hofman, L Emmett, J Calais, ... European journal of nuclear medicine and molecular imaging 50 (9), 2830-2845, 2023 | 131 | 2023 |
| Novel framework for treatment response evaluation using PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study A Gafita, I Rauscher, M Weber, B Hadaschik, H Wang, WR Armstrong, ... Journal of Nuclear Medicine 63 (11), 1651-1658, 2022 | 122 | 2022 |
| Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT] J Calais, J Czernin, WP Fendler, D Elashoff, NG Nickols BMC cancer 19, 1-11, 2019 | 122 | 2019 |